Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have
revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of …

Focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, is a vital
participant in primary cellular functions, such as proliferation, survival, migration, and …

Triple-negative breast cancer (TNBC) is currently the worst prognostic subtype of breast
cancer, and there is no effective treatment other than chemotherapy. Processing of …

Triple-negative breast cancer (TNBC) is the most malignant breast cancer, with high rates of
relapse and metastasis. Because of the nonspecific targeting of chemotherapy and …

Introduction Immunotherapy has revolutionized cancer treatment, including TNBC, which
has limited options of treatment and poor prognosis. ICIs studied in TNBC include …

Among breast cancers, triple-negative breast cancer (TNBC) has been recognized as the
most aggressive type with a poor prognosis and low survival rate. Targeted therapy for …

Female-specific cancers, particularly breast, cervical, ovarian, and uterine cancers, account
for nearly 40% of all cancers in women. This study aimed to analyze the global …

Triple-negative breast cancer (TNBC) tumors are biologically aggressive breast cancer. On
the molecular level, TNBC is a highly heterogeneous disease; more biotechnologies are …

Triple negative breast cancer (TNBC) displays a notable challenge in clinical oncology due
to its invasive nature which is attributed to the absence of progesterone receptor (PR) …

Triple-negative breast cancer (TNBC) represents a highly aggressive and heterogeneous
malignancy. Currently, multitarget drug approaches present a promising therapeutic …